Peptides DB
Research-centric peptide and protocol reference hub
Study 3 of 6CJC-1295 literaturePubMed2023

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

The study presents a validated method for detecting GHRHs in urine with a limit of detection of 0.2 ng/mL, which may be useful for anti-doping screening.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the cjc-1295 corpus
4
Preclinical · this one
0
Observational
0
Open-label
0
Randomised
2
Reviews

Summary and findings

This study developed and validated a method for detecting growth hormone-releasing hormones (GHRHs) in urine samples, including CJC-1295. The method achieved a limit of detection (LOD) of 0.2 ng/mL and a limit of quantification (LOQ) of 0.6 ng/mL. The findings suggest that the method is suitable for routine screening in anti-doping laboratories.

How much of this paper we could read: partial text (0.50). We had some abstract detail. Check the source for anything decisive. What this means →
LOD of 0.2 ng/mL.2023

Abstract

The authors’ words, as PubMed supplied them

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH<sub>2</sub>, somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL, and linearity across the range of 0.1 ng/mL to 1.2 ng/mL. The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

Background

The paper addresses the detection of growth hormone-releasing hormones (GHRHs) in urine, which is significant for understanding their role in various physiological processes. Prior methods for detecting GHRHs may have limitations in sensitivity and specificity. This study aims to improve detection methods, which could enhance research and clinical assessments involving GHRHs.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the CJC-1295 corpus

BInjectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.europepmc · 2026HumanBInjectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.PubMed · 2026HumanDSemantic Scholar search for CJC-1295SemanticScholar · 2010DChromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.PubMed · 2024 · Not reported in abstract.DAnalysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.PubMed · Achieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL).